 |
|
|
| |
Viral kinetics and sequence analysis of a Phase I monotherapy study in subjects with chronic hepatitis B reveals a high barrier of resistance to the capsid assembly modulator ALG-000184
|
| |
| |
EASL 2025 May 7-10 Amsterdam
Andreas Jekle1, Kathy Jackson2, Jacinta O'Keefe2, Ros Edwards2, Lilly Yuen2, Doris Chibo2, Thanh Van1, Jen Rito1,
Maida Maderazo1, Julian A. Symons1, Lawrence Blatt1, Rolando Viani1,
Kha Le1, Hardean E. Achneck1, Tse-I Lin3 and Min Wu1
1Aligos Therapeutics, Inc., South San Francisco, CA, USA; 2Victorian Infectious Diseases Reference Laboratory,
Royal Melbourne Hospital, at the Peter Doherty Institute for Infection and Immunity, Victoria, Australia; 3Aligos Belgium BV, Leuven, Belgium.
|
| |
|
|
|
|
|
